

Mara Reig

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5129924/maria-reig-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

10,264
citations

36
h-index

101
g-index

139
ext. papers

13,163
ext. citations

6
avg, IF

6.97
L-index

#	Paper	IF	Citations
113	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.. <i>Lancet Oncology, The</i> , 2022 , 23, 4-6	21.7	0
112	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology Y Hepatologia</i> , 2022 ,	0.9	
111	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 428-428	2.2	0
110	HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	11
109	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
108	Reply to: "Correspondence on the".. <i>Journal of Hepatology</i> , 2022 ,	13.4	
107	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
106	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , 2021 ,	13.4	127
105	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 263-270	3	2
104	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021 , 12, 440-449	3.3	0
103	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
102	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , 2021 , 156, 463.e1-463.e30	1	2
101	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
100	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
99	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021 , 74, 1225-1233	13.4	14
98	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 463.e1-463.e30	0.3	0
97	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260	0.3	11

96	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021 , 75, 1154-1163	13.4	3
95	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021 , 13,	6.6	13
94	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021 , 9, 655-661	5.3	1
93	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021 , 41, 598-607	7.9	4
92	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
91	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \geq cm in cirrhotic patients. <i>European Radiology</i> , 2021 , 31, 4794-4803	8	3
90	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021 , 135, 109484	4.7	9
89	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. <i>Antioxidants</i> , 2021 , 10,	7.1	2
88	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021 , 27, 1767-1778	4.5	3
87	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021 , 75, 600-609	13.4	25
86	Current pharmacological treatment of hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2021 , 60, 141-148	5.1	3
85	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104313	2.6	2
84	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1041-1046	3.3	7
83	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020 , 40, 1467-1476	7.9	8
82	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020 , 30, 6694-6701	8	3
81	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 320-341	13.4	68
80	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020 , 12,	6.6	9
79	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	3

78	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 710-719	2.4	10
77	Reply to: "The reported clear cut time association between interferon-free treatment and HCCRs anything but clear cut". <i>Journal of Hepatology</i> , 2020 , 72, 1036-1037	13.4	1
76	Letter: are sorafenib-related adverse events associated with prolonged survival? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 192	6.1	
75	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020 , 24, 719-737	4.6	14
74	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
73	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020 , 12,	6.6	6
72	Performance of gadoteric acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020 , 30, 186-194	8	11
71	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 482-491	6.1	30
70	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44
69	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , 2019 , 71, 447-448	13.4	44
68	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. <i>Viruses</i> , 2019 , 11,	6.2	5
67	SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program. <i>Journal of Hepatology</i> , 2019 , 70, e845	13.4	2
66	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 17-29	10.3	26
65	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019 , 103, 39-44	1.8	33
64	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 617-630	24.2	82
63	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019 , 19, 3176-3184	8.7	43
62	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterologia Y Hepatologia (English Edition)</i> , 2019 , 42, 502-511	0.1	
61	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 327-327	2.2	64

60	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 502-511	0.9	6
59	New Systemic Treatments in Advanced Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2019 , 25, 311-322	2.5	17
58	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , 2018 , 19, 682-693	21.7	216
57	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
56	New trials and results in systemic treatment of HCC. <i>Journal of Hepatology</i> , 2018 , 69, 525-533	13.4	39
55	Lenvatinib: can a non-inferiority trial change clinical practice?. <i>Lancet</i> , 2018 , 391, 1123-1124	4.0	10
54	Hepatocellular carcinoma. <i>Lancet</i> , 2018 , 391, 1301-1314	4.0	2402
53	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018 , 67, 612-622	11.2	44
52	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 16701-16717	3.3	32
51	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 328-349	0.1	1
50	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018 , 68, 16-24	14.4	89
49	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37 Suppl 1, 136-139	7.9	25
48	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica</i> , 2017 , 149, 61-71	1	13
47	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017 , 37, 109-118	7.3	59
46	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017 , 149, 61-71	0.3	1
45	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4000-4000	2.2	26
44	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017 , 23, 2448-2452	5.6	9
43	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 117-131	0.3	

42	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016 , 65, 864-865	13.4	6
41	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016 , 34, 597-602	3.2	51
40	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016 , 64, 1090-1098	13.4	407
39	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016 , 150, 835-53	13.3	1012
38	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016 , 65, 719-726	13.4	709
37	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1923-36	4	12
36	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016 , 146, 511.e1-511.e22	0.3	1
35	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 751-2	21.7	3
34	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015 , 33, 590-7	3.2	1
33	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
32	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules. <i>Journal of Hepatology</i> , 2015 , 62, 150-5	13.4	28
31	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. <i>Hepatology</i> , 2015 , 61, 526-36	11.2	207
30	Reply: To PMID 25212123. <i>Hepatology</i> , 2015 , 62, 978-9	11.2	
29	Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. <i>Annals of Surgery</i> , 2015 , 261, e105	7.8	8
28	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 921-35	2.5	9
27	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014 , 61, 164-5	13.4	3
26	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014 , 61, 318-24	13.4	172
25	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , 2014 , 34, 444-55	7.3	83

24	Treatment of hepatocellular carcinoma. <i>Digestive Diseases</i> , 2014 , 32, 554-63	3.2	29
23	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , 2013 , 58, 2023-31	11.2	162
22	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013 , 49, 3412-9	7.5	178
21	Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 1197-9	2.4	2
20	Evoluci3 natural y estratificaci3 del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013 , 2, S333-S360	2.2	78
19	Management of HCC. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S75-87	13.4	438
18	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012 , 1, 183-185	2.2	4
17	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012 , 56, 103-8	13.4	114
16	Non-invasive diagnosis of hepatocellular carcinoma 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012 , 56, 1317-23	13.4	135
15	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012 , 56, 1330-5	13.4	354
14	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , 2012 , 61, 1481-7	19.2	121
13	The search for an effective partner for sorafenib: the failure of doxorubicin. <i>Gastroenterology</i> , 2011 , 140, 1687-8	13.3	1
12	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , 2011 , 54, 2238-44	11.2	84
11	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , 2010 , 30, 61-74	7.3	770
10	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S242-8	3.3	27
9	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. <i>Annual Review of Medicine</i> , 2010 , 61, 317-28	17.4	189
8	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010 , 17, 420-1	2.8	1
7	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010 , 51, 2020-9	11.2	209

6	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 791-8	11.2	207
5	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , 2009 , 115, 616-23	6.4	359
4	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009 , 29 Suppl 1, 148-58	7.9	19
3	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , 2009 , 137, 26-9	13.3	77
2	Sorafenib for hepatocellular carcinoma: global validation. <i>Gastroenterology</i> , 2009 , 137, 1171-3	13.3	4
1	Tumors of the Liver773-785		